Lixte Biotechnology Holdings Inc. - Rasio nilai perusahaan marang dodolan LIXT

Lixte Biotechnology is scaling combined oncology therapies through partnerships with global centers. This linear chart of the EV/Revenue ratio on GURU.Markets demonstrates business resilience, with the indicator standing at 0.00. The development of inhibitors for various tumors mitigates risks, although geopolitical tensions and sanctions are currently hindering reagent logistics and the execution of international clinical trials.
Lixte Biotechnology Holdings - rincian analitis lan metrik utama (LIXT)

The EV/Sales metric determines the market value of a business relative to its revenue, excluding the impact of leverage to identify the net value of the generated cash flow. By analyzing the EV/Sales valuation chart on GURU.Markets, an investor can see the speculative value of Lixte Biotechnology (LIXT), which, at its current stage of R&D in oncotherapy, does not rely on commercial sales, turning the indicator into a reflection of expectations for future innovations.